IGM Biosciences, Inc.

Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager. The French f

In September, IGM Biosciences decided to pivot into autoimmune diseases after failure in oncology, but the strategy has already foundered. The company has halted development of its two lead candidat

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Partners With MedinCell On Up To